Welcome to our dedicated page for Immuron American Depositary Shares news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron American Depositary Shares stock.
Immuron Limited (NASDAQ: IMRN) is a pioneering Australian biopharmaceutical company that specializes in oral immunotherapy. The company focuses on developing and commercializing therapies utilizing polyclonal antibody products that target the human gut immune system and microbiome. Immuron's cutting-edge technology platform is designed to create orally stable therapeutics, offering potential 'oral targeted therapy' for a variety of immune-mediated and inflammatory disorders, including non-alcoholic steatohepatitis (NASH), diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis, and other chronic conditions influenced by the immune system.
These disorders represent growing areas of unmet medical need, where oral targeted therapy drugs could provide significant benefits due to their high safety profiles and minimal absorption. Immuron has successfully brought one product to market, serving as proof of concept for its oral immune technology platform. Additionally, the company boasts a robust pipeline of products in various stages of clinical development.
One of Immuron's prominent products is IMM-124E, a proprietary immunomodulatory agent aimed at treating gastrointestinal immune-mediated diseases, including fatty liver diseases. The company operates in two primary segments: Research and Development, and Hyperimmune Products.
Recent developments highlight Immuron's progress in the market. The company has reported increased sales of its travel-related product, Travelan®, especially in markets such as the USA and Canada. Notably, sales in the USA have exceeded expectations following the product’s launch on Amazon. The company is also exploring non-dilutive funding opportunities for its Phase 3 clinical trials and has filed a provisional patent application with the U.S. Patent Office to protect its innovative findings.
Immuron's strategy involves continuing to harness its unique oral immunotherapy platform to address significant medical needs, focusing on partnerships and collaborations to enhance its product offerings and market reach.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported significant sales growth for FY22. North American sales of Travelan® surged by 494%, reaching AU $0.6M, while global sales rose 431% to AU $0.9M. Sales in the US were particularly strong, increasing from AU $4K in FY21 to AU $0.6M in FY22, driven by sales through Passport Health Travel Clinics and Amazon. In Australia, sales of Travelan® and Protectyn® also grew, totaling AU $0.3M in FY22. Immuron aims to expand its product portfolio while benefiting from the recovering travel sector.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced receiving a notification of the Intent to Grant a European Patent for treatments related to Clostridioides difficile associated disease. This patent, numbered 14784945.9, focuses on methods and compositions for both treatment and prevention of the infection. Alongside patents in Australia, New Zealand, and the U.S., this grant strengthens Immuron's intellectual property in an area with significant health and economic impact, as Clostridioides difficile infections can result in severe complications and considerable healthcare costs globally.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced that the US Naval Medical Research Center (NMRC) submitted an IND application to the FDA for a new oral therapeutic targeting Campylobacter and ETEC. This initiates two human phase II clinical trials, with one trial aimed at preventing infectious diarrhea caused by ETEC, set to start in July 2022, and another focused on moderate to severe campylobacteriosis. The trials will recruit 60 volunteers, testing the product's safety and efficacy against these pathogens.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) provides an update on its clinical trial evaluating the efficacy of Travelan® against two non-antibiotic products for Travelers’ Diarrhea (TD). Manufacture of investigational medical products is complete, and initial shipments have been dispatched. The clinical protocol has been amended to extend the treatment period from 13 to 22 days due to COVID-19 quarantine requirements. Planned enrollment of 1,336 participants is expected to begin in June 2022, with completion anticipated within 18 months.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Steven Lydeamore as CEO, effective June 27, 2022. With 30 years of pharmaceutical experience, including roles at Apotex and Mayne Pharma, Lydeamore has a strong background in mergers, acquisitions, and product development. He aims to leverage opportunities for Immuron's products, Travelan® and Protectyn®, and enhance the company's IP portfolio. Interim CEO Dr. Jerry Kanellos will transition to COO, acknowledging the challenges faced during his tenure. The company is focused on expanding clinical trials in partnership with the U.S. Department of Defense.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported strong sales growth for its gastrointestinal supplement Travelan® in Q3 FY22. North American sales surged 185% year-over-year, while global sales increased by 216%, totaling AU $193K compared to AU $61K in Q3 FY21. Year-to-date results show AU $392K in worldwide sales, marking a 340% increase. Sales in the US reached AU $153K for Q3 FY22, primarily driven by partnerships with Passport Health Travel Clinics and e-commerce platforms. Positive sales trends are attributed to the recovery of international travel.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has made significant progress in its bid for additional funding from the U.S. Department of Defense. The company is seeking AU$5.4M (US$4M) for its Travelan product, deemed eligible for award. The Investigational New Drug application is advancing, with plans for a clinical trial involving 60 healthy volunteers in the USA. This trial will focus on preventing travelers' diarrhea caused by bacterial pathogens, amidst concerns regarding antibiotic resistance and the need for effective preventive treatments.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Paul Brennan as an independent Non-Executive Director, effective March 16, 2022. Brennan's extensive healthcare experience includes his role as CEO of PolyNovo Limited, where he grew the company significantly. His appointment is expected to leverage Immuron's unique intellectual property in gut health and enhance its clinical research capabilities. Non-Executive Chairman Dr. Roger Aston expressed confidence in Brennan's diverse background, which includes technology commercialization and international marketing.
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical firm, has successfully claimed a cash refund of AUD $306,154 under the Australian Government’s Research and Development Income Tax Concession program. This refund pertains to eligible research and development expenses from the 2021 Financial Year. The company is committed to developing oral immunotherapeutics for gut-mediated pathogens.
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, has received a European Patent for treating travelers' diarrhea. The patent, granted on January 5, 2022, covers 'Composition and method for the treatment and prevention of enteric bacterial infections.' This extends Immuron's patent coverage across multiple regions, including Australia, India, Canada, and the US. Given the rising antibiotic resistance in enteric pathogens, this patent validates a preventative approach that addresses a critical health issue prevalent among travelers and military personnel.
FAQ
What is the current stock price of Immuron American Depositary Shares (IMRN)?
What is the market cap of Immuron American Depositary Shares (IMRN)?
What does Immuron Limited do?
What are some diseases Immuron targets with its therapies?
What is IMM-124E?
How many segments does Immuron operate in?
What recent achievements has Immuron reported?
What are Immuron's future plans?
How is Immuron expanding its market presence?
What makes Immuron's therapies unique?
Has Immuron filed any patents recently?
What is Travelan®?
